Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed, page-5

  1. 5 Posts.
    The mouse data is one thing but hidden in the JNM published article (sits behind a paywall) in the results section the authors note "2 participants ceased due to exceptional responses". The discussion does not elaborate. Not sure if this is an 'abscopal' response they talk up but 2/56 sounding like they were cured is significant. The report concludes with recommending a phase III (randomised controlled) trial.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
6.7¢
Change
-0.001(1.47%)
Mkt cap ! $19.57M
Open High Low Value Volume
6.7¢ 6.8¢ 6.7¢ $6.53K 97.42K

Buyers (Bids)

No. Vol. Price($)
1 59378 6.6¢
 

Sellers (Offers)

Price($) Vol. No.
6.7¢ 10252 1
View Market Depth
Last trade - 13.53pm 21/07/2025 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.